Brian Park, PharmD, Author at MPR

Brian Park, PharmD

All articles by Brian Park, PharmD

Enhertu Approved for Unresectable or Metastatic HER2-Positive Breast Cancer

The Food and Drug Administration (FDA) has granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki; AstraZeneca and Daiichi Sankyo) for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2-based regimens in the metastatic setting.  The approval was based on results from the phase 2, open-label, single-group,…

Diagnostic Test for Rapid MRSA Detection Gets Market Clearance

The Food and Drug Administration (FDA) has authorized marketing of a new diagnostic test, cobas vivoDx MRSA (Roche Molecular Systems Inc), to detect methicillin-resistant Staphylococcus aureus (MRSA) bacterial colonization and aid in the prevention and control of MRSA infections in healthcare settings. The cobas vivoDx MRSA test provides rapid phenotypic detection of MRSA colonization through…